Assessment of Sex Hormones and Gonadotropins levels in Alzheimer Patients

  • Fariba Karimi Endocrinology and Metabolism Research Center, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran
  • Afshin Borhani Haghighi Clinical Neurology Research Center, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran
  • Payman Petramfar Clinical Neurology Research Center, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran
  • Arnoosh Afreidoon Endocrinology and Metabolism Research Center, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran
Keywords: Alzheimerʾs disease, Sex Hormones, Gonadotropins, Sex Hormone Binding Globulin (SHBG)


Backgrounds: Increasing age is the most significant risk factor for Alzheimerʾs disease and depletion of sex hormones is an important consequence of normal aging. This study aimed to investigate the serum level of sex hormones and gonadotropins in patients with Alzheimerʾs disease in comparison with the control group. Materials and Methods: This case-control study was conducted between October 2010 and November 2011 in Shiraz Mottahari Clinic. Fifty-one patients with Alzheimer’s disease and 49 age-matched volunteers without dementia participated in this survey. Both groups were evaluated by two neurologists according to DSM- IV criteria. Blood samples were taken after 12 hours fasting to measure serum levels of estradiol, testosterone, gonadotropins and sex hormone binding globulin (SHBG). Results: Eighteen females and 33 males in the patient group, and 23 females and 26 males in the control group participated. There were no significant differences between the two groups regarding their gonadotropins, estradiol, free androgen index and body mass index, but the mean level of SHBG in patients was significantly higher than the control group (P=0.03). In addition, male patients had a higher total testosterone mean compared to male subjects in the control group (P=0.02). Conclusion: Our findings regarding testosterone levels in males of two groups were contrary to some of the previous surveys in this area. Moreover, we found higher levels of SHBG in patients compared to the control subjects. Further investigation is needed to define whether and how changes of sex hormones can affect brain health and vulnerability to Alzheimer’s disease.[GMJ.2015;4(4):139-45]

Author Biography

Fariba Karimi, Endocrinology and Metabolism Research Center, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran
Department  of internal medicine, Assistant professor of Endocrinology and Metabolism


Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013; 80(19): 1778-83.

Castellani RJ, Rolston RK, Smith MA. Alzheimer disease. Dis Mon. 2010; 56(9): 484-546.

Prince M, Bryce R, Albanese E, Wimo A, Riberio W, Ferri CP. The global prevalence of dementia: A systematic review and meta-analysis. Alzheimer Dement. 2013; 9(1): 63-75.

Blair AJ, McGee H, Bhatta S, Palm R, Casadesus G. Hypothalamic-pituitary-gonadal axis involvement in learning and memory and Alzheimer’s disease: more than “ just” estrogen. Front Endocrinol (Lausanne). 2015; 6: 45.

Geerlings MI, Launer LJ, de Jong FH, Ruitenberg A, Stijnen T, van Swieten JC, et al. Endogenous estradiol and risk of dementia in women and men: the Rotterdam study. Ann Neurol. 2003; 53(5): 607-15.

Pauline M. Maki, Victor W. Henderson. Hormone therapy, dementia, and cognition: the Womenʾs Health Initiative ten years on. Climacteric. 2012; 15(3): 256-62.

Hogervorst E, Bandelow S, Combrinck M, Smith AD. Low free testosterone is an independent risk factor for Alzheimerʾs disease. EXP Gerontol. 2004; 39(11-12): 1633-9.

Rosario RE, Chang L, Beckett LT, Carroll CJ, Murphy MP, Stanczyk ZF, et al. Age-related changes in serum and brain levels of androgens in male brown Norway rats. Neuroreport. 2009; 20(17): 1534-7.

Rosario RE, Chang L, Head HE, Stanczyk ZF, Pike K. Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer’s disease. Neurobiol Aging. 2011; 32(4): 604-13.

Verdile G, Laws SM., Henley D, Ames D, Bush AI, Ellis KA, et al. Associations between gonadotropins, testosterone and ß-amyloid in men at risk of Alzheimer’s disease. Molecular Psychiatry. 2014; 19(1): 69-75.

Hyde Z, Flicker L, Almeida OP, McCaul KA, Jamrozik K, Hankey GJ, et al. Higher luteinizing hormone is associated with poor memory recall: the health in men study. J Alzheimers Dis. 2010; 19(3): 943–51.

Apaja PM, Harju KT, Aatsinki JT, Petȁjȁ -Repo UE, Rajaniermi HJ. Identification and structural characterization of the neuronal luteinizing hormone receptor associated with sensory systems. J Biol Chem. 2004; 279(3): 1899-906.

Short RA, Bowen RL, O'Brien PC, Graff-Radford NR. Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc. 2001; 76(9): 906-9.

Bryan KJ, Mudd JC, Richardson SL, Chang J, Lee HG, Zhu X, et al. Down-regulation of serum gonadotropins is as effective as estrogen replacement at improving menopause-associated cognitive deficits. J Neurochem. 2010; 112(4): 870-81.

Palm R, Chang J, Blair J, Garcia-Mesa Y, Lee HG, Castellani RJ, et al. Downregulation of serum gonadotropins but not estrogen replacement improves cognition in aged-ovariectomized 3xTg AD female mice. J Neurochem. 2014; 130(1): 115–25.

Dubal B D, Broestl L, Worden K. Sex and gonadal hormones in mouse models of Alzheimerʾs disease: what is relevant to the human condition? Biol Sex Differ. 2012; 3: 24.

Sherwin BB. Estrogen and cognitive functioning in women. Exp Biol Med (Maywood). 1998; 217(1): 17–22.

Garcia-Segura LM, Azcoitia I, DonCarlos LL. Neuroprotection by estradiol. Prog Neurobiol. 2001; 63(1): 29–60.

Pennanen C, Laakso MP, Kivipelto M, Ramberg J, Soininen H. Serum testosterone levels in males with Alzheimer's disease. J Neuroendocrinol. 2004; 16(2): 95-98.

Almeida OP, Riana A, Clarnette R, Martins RN. Decreased plasma testosterone levels in Alzheimerʾs disease and aged controls from Australia. Alzheimerʾs Rep. 2000; 3: 15-18.

Hogervorst E, Lehmann DJ, Warden DR, McBroom J, Smith AD. Apolipoprotein E epsilon4 and testosterone interact in the risk of Alzheimer’s disease in men. Int J Geriatr Psychiatry. 2002; 17(10): 938-40.

Hiltuen M, Livonen S, Soininen H. Aromatase enzyme and Alzheimer’s disease. Minerva Endocrinol. 2006; 31(1): 61-73.

Huang R, Poduslo SE. CYP19 haplotypes increase risk for Alzheimer’s disease. J Med Genet. 2006; 43(8): e42.

Twist SJ, Taylor GA, Weddell A, Weightman DR, Edwardson JA, Morris CM. Brain oestradiol and testosterone levels in Alzheimerʾs disease. Neurosci Lett. 2000; 286(1): 1-4.

Paoletti AM, Congia S, Lello S, Tedde D, Orrú M, Pistis M, et al. . Low androgenization index in elderly women and elderly men with Alzheimerʾs disease. Neurology. 2004; 62(2): 301-3.

Muller M, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. Sex hormone binding globulin and incident Alzheimer’s disease in elderly men and women. Neurobiol Aging. 2010; 31(10): 1758-65.

Caldwell JD, Suleman F, Chou SH, Shapiro RA, Herbert Z, Jirikowski GF. Emerging roles of steroid-binding globulins. Horm Metab Res. 2006; 38(4): 206-18.

Rosario ER, Carroll J, Pike CJ. Testosterone regulation of Alzheimer like neuropathology in male 3xTg-AD mice involves both estrogen and androgen pathways. Brain Res. 2010; 1359(4): 281–90.

How to Cite
Karimi, F., Borhani Haghighi, A., Petramfar, P., & Afreidoon, A. (2015). Assessment of Sex Hormones and Gonadotropins levels in Alzheimer Patients. Galen Medical Journal, 4(4), 139-45.
Original Article